DOCSLIB.ORG

Additional Use of Glycated Hemoglobin for Diagnosis of Type 2 Diabetes in People Undergoing Coronary Angiography Reveals a Subgroup at Increased Cardiovascular Risk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Additional Use of Glycated Hemoglobin for Diagnosis of Type 2 Diabetes in People Undergoing Coronary Angiography Reveals a Subgroup at Increased Cardiovascular Risk Cardiovascular and Metabolic Risk BRIEF REPORT Additional Use of Glycated Hemoglobin for Diagnosis of Type 2 Diabetes in People Undergoing Coronary Angiography Reveals a Subgroup at Increased Cardiovascular Risk 1,2 5 GUENTHER SILBERNAGEL, MD BERNHARD R. WINKELMANN, MD diagnosis as per the ADA 2009 definition 1,3 6 MARCUS E. KLEBER, PHD BERNHARD O. BOEHM, MD 4 3,4,7 are at increased risk of death from any cause TANJA B. GRAMMER, MD WINFRIED MÄRZ, MD and from cardiovascular diseases (10,11). RESEARCH DESIGN AND OBJECTIVEdTo study the prognosis of people with newly diagnosed type 2 diabetes as per d fi METHODS LURIC is a cross-sectional the American Diabetes Association (ADA) 2010 de nition but without diabetes as per the ADA and prospective clinical trial that was de- 2009 definition. signed to investigate cardiovascular risk RESEARCH DESIGN AND METHODSdA total of 2,002 participants of the Ludwigshafen factors. A total of 3,316 white subjects Risk and Cardiovascular Health (LURIC) study without a history of diabetes were studied. were recruited between July 1997 and January 2000 at the Ludwigshafen Heart RESULTSdDuring the follow-up of a mean duration 6 SD of 7.7 6 2.0 years, 346 people died fi n Center in southwestern Germany (10,11). (202 cardiovascular deaths). Subjects with type 2 diabetes as per the ADA 2009 de nition ( = All participants underwent coronary angi- 468) had significantly increased all-cause and cardiovascular mortality compared with people without diabetes as per the ADA 2010 definition (both P # 0.003). Subjects with type 2 diabetes ography. The precise inclusion/exclusion as per the ADA 2010 definition but without diabetes as per the ADA 2009 definition (n =150) criteria have been previously described were at significantly increased risk to die of cardiovascular diseases (P =0.029). (10,11). For the present analyses, subjects with known diabetes or incomplete deter- CONCLUSIONSdUse of the ADA 2010 diabetes definition may be instrumental in improv- mination of the glucometabolic pheno- ing cardiovascular risk stratification in people undergoing coronary angiography. type (missing 75-g oral glucose tolerance test despite fasting glucose ,126 mg/dL) were additionally ruled out. Information on the cause of death was missing for ccording to the 2009 guidelines of Of particular interest, recent data from 11 decedents. These people were ex- Athe American Diabetes Association the Atherosclerosis Risk in Communities cluded when data on cardiovascular (ADA), subjects with increased fast- (ARIC) study and the Ludwigshafen Risk mortality were analyzed. The study was ing glucose ($126 mg/dL) and/or post- and Cardiovascular Health (LURIC) approved by the ethics committee at the challenge glucose ($200 mg/dL) are study have shown that glycated hemoglo- Ärztekammer Rheinland-Pfalz and was diagnosed with diabetes (1). Using the bin is a better predictor for all-cause and conducted in accordance with the Declara- ADA 2010 criteria, subjects with isolated cardiovascular mortality than fasting glu- tion of Helsinki. Informed written consent elevation of glycated hemoglobin $6.5% cose (9,10). was obtained from all participants (10). Di- (fasting glucose ,126 mg/dL, postchal- The objective of the present work in abetes was diagnosed according to the lenge glucose ,200 mg/dL) are also con- 2,002 LURIC participants was to analyze 2009 and 2010 criteria of the ADA (1,2). sidered diabetic individuals (2). whether subjects with newly diagnosed The follow-up for all-cause and cardiovas- Glycated hemoglobin has been asso- type 2 diabetes as per the ADA 2010 de- cular mortality had a mean duration 6 SD ciated with macrovascular disease (3–8). finition who would not have received the of 7.7 6 2.0 years. ccccccccccccccccccccccccccccccccccccccccccccccccc Laboratory analyses From the 1Ludwigshafen Risk and Cardiovascular Health Study Nonprofit LLC, Freiburg, Germany; the The laboratory methods have been reported 2Division of Endocrinology, Diabetology, Nephrology, Vascular Disease, and Clinical Chemistry, De- previously (10,11). Glucose was measured partment of Internal Medicine, Eberhard-Karls-University Tübingen, Tübingen, Germany; the 3Synlab enzymatically on a Hitachi 717 analyzer Center of Laboratory Diagnostics Heidelberg, Heidelberg, Germany; the 4Mannheim Institute of Public (Roche, Mannheim, Germany). Glycated Health, Social and Preventive Medicine, Mannheim Medical Faculty, University of Heidelberg, Mannheim, hemoglobinwasmeasuredwithanimmu- Germany; the 5Cardiology Group Frankfurt-Sachsenhausen, Frankfurt, Germany; the 6Division of Endo- crinology, Department of Internal Medicine, Ulm University, Ulm, Germany; and the 7Clinical Institute of noassay (hemoglobin A1c UNIMATE 5; Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. Hoffmann-LaRoche, Grenzach-Whylen, Corresponding author: Winfried März, [email protected]. Germany). Received 2 June 2011 and accepted 15 August 2011. DOI: 10.2337/dc11-1046 Statistical analysis © 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/ The baseline clinical and biochemical licenses/by-nc-nd/3.0/ for details. characteristics are presented for three care.diabetesjournals.org DIABETES CARE 1 Diabetes Care Publish Ahead of Print, published online September 12, 2011 Diabetes categorization and mortality groups: group A, subjects without diabe- Table 1dBaseline characteristics according to diabetes definition tes as per the ADA 2010 definition (with- out diabetes); group B, subjects with type fi No diabetes 2 diabetes as per the ADA 2010 de nition as per ADA 2010 T2DM ADA T2DM ADA but without diabetes as per the ADA 2009 definition 2010 2009 P value* definition (T2DM ADA 2010); and group C, subjects with type 2 diabetes as per the n 1,384 150 468 d ADA 2009 definition (T2DM ADA 2009). Male sex 1,012 (73.1) 113 (75.3) 342 (73.1) 0.839 Categorical data are expressed as numbers Age (years) 60.6 6 10.8 62.7 6 9.2 64.6 6 9.5 ,0.001 and percentages. In the case of continu- Fasting glucose (mg/dL) 98 6 10 103 6 11 125 6 28 ,0.001 ous variables, we report means with SDs Glucose 2 h (mg/dL)† 125 6 33 137 6 30 233 6 65 ,0.001 or medians with interquartile ranges. Fasting insulin (mU/L) 8 (6–12) 9 (6–12) 12 (8–21) ,0.001‡ 6 6 6 , P values for differences in baseline char- Hemoglobin A1c (%) 5.7 0.4 6.8 0.5 6.5 1.0 0.001 acteristics among the three groups were BMI (kg/m2) 27.1 6 3.8 28.0 6 4.3 28.2 6 4.0 ,0.001 calculated with the x2 test for categorical Waist circumference (cm)x 97 (12) 101 (11) 101 (11) ,0.001 data and with ANOVA for continuous Systemic hypertension 920 (66.5) 112 (74.7) 379 (81.0) ,0.001 variables. Triglycerides and insulin were Blood lipid level (mg/dL) transformed logarithmically before being Total cholesterol 196 6 38 189 6 37 193 (40) 0.073 used in parametric statistical procedures. LDL cholesterol 120 6 35 117 6 31 116 6 34 0.097 The Cox proportional hazards model was HDL cholesterol 40 6 11 38 6 10 37 6 10 ,0.001 used to test the relationships of the three Triglycerides 137 (103–190) 140 (108–187) 158 (120–222) ,0.001‡ groups with all-cause and cardiovascular Glomerular filtration rate mortality. Two predefined models of (mL/min/1.73 m2)846 17 80 6 18 81 6 18 ,0.001 adjustment were used (model 1: univari- Smoking 0.074 ate; model 2: adjusted for sex, age, BMI, Never 501 (36.2) 48 (32.0) 153 (32.7) d hypertension, smoking, glomerular fil- Former smoker 597 (43.1) 64 (42.7) 232 (49.6) d tration rate, triglycerides, LDL choles- Current smoker 286 (20.7) 38 (25.3) 83 (17.7) d terol, and HDL cholesterol). The results Coronary artery disease are presented as hazard ratios with 95% (50% stenosis) 869 (62.8) 102 (68.0) 344 (73.5) ,0.001 CIs. All statistical tests were two-sided Medication use and P , 0.05 was considered significant. b-Blocker 889 (64.2) 88 (58.7) 303 (64.7) 0.369 The SPSS 15.0 statistical package (SPSS ACE inhibitor 667 (48.2) 78 (52.0) 258 (55.1) 0.031 Inc., Chicago, IL) was used. Calcium antagonist 180 (13.0) 19 (12.7) 87 (18.6) 0.010 Diuretic 250 (18.1) 43 (28.7) 166 (35.5) ,0.001 RESULTSdThe clinical and biochemi- Statin 656 (47.4) 75 (50.0) 234 (50.0) 0.561 cal characteristics of the study partici- Acetyl salicylic acid 983 (71.0) 118 (78.7) 322 (68.8) 0.068 pants and data on mortality are shown in Mortality Table 1. A total of 346 (17.3%) deaths All-cause death 194 (14.0) 30 (20.0) 122 (26.3) d occurred during the follow-up. Among Cardiovascular death|| 111 (8.1) 22 (14.8) 69 (14.9) d these, 202 (58.4%) were accounted for Data are n (%) in cases of categorical data and means 6 SDs or medians (25th–75th percentiles) in cases of by cardiovascular diseases. Compared continuous variables. *x2 test and ANOVA for categorical and continuous data, respectively. †n = 1,384/150/ ‡ xn n with subjects without diabetes, people 238. ANOVA of logarithmically transformed values. = 1,363/149/461. || = 1,378/149/464. with T2DM ADA 2009 (hazard ratio 2.02 [95% CI 1.61–2.53]; P , 0.001) and those with T2DM ADA 2010 (1.54 remained significant after multivariate ad- ADA 2009 and those with T2DM ADA [1.05–2.26]; P = 0.028) had increased justment for both subjects with T2DM 2010.
Load more

Recommended publications
  • Role of Cardiovascular Risk Factors in Prevention and Treatment of Macrovascular Disease in Diabetes
    CONSENSUS STATEMENT American Diabetes Association Role of Cardiovascular Risk Factors in Prevention and Treatment of Macrovascular Disease in Diabetes iabetes mellitus is a major risk factor for mor- The conference consisted of 19 invited presentations bidity and mortality due to coronary heart dis- and considerable discussion from a large audience of ease, cerebrovascular disease, and peripheral health-care professionals. A consensus panel with ex- D vascular disease in the United States. The prev- pertise in clinical diabetes, clinical investigation, epi- alence of these macrovascular complications is in- demiology, nutrition, cardiovascular diseases (CVD), creased about two- to fourfold in diabetic populations. and lipid and lipoprotein disorders considered a broad In 1987, these macrovascular complications accounted spectrum of issues concerned with macrovascular dis- for most of the hospitalizations for diabetes and contrib- ease in diabetes. The panel reached a consensus on uted substantially to the 20.4 billion dollars spent for answers to the following questions: diabetes care in the United States. Multiple risk factors for macrovascular disease are fre- 1. The commonly identified risk factors for macro- quently found in individuals with diabetes. There is an vascular disease include hypertension, smoking, increased prevalence of hypertension and lipid abnor- and lipid abnormalities. To what extent do these malities in many populations with diabetes. Many in- risk factors operate in people with diabetes? dividuals with diabetes have not stopped smoking 2. Are cardiovascular risk factors and cardiovascular despite evidence that this is a major cardiovascular risk risk the same in all types of diabetes, and are there factor. There are other factors that may be associated other risk factors of importance to people with di- with macrovascular disease in diabetes, including obe- abetes? sity, impaired glucose tolerance (IGT), hyperglycemia, 3.
    [Show full text]
  • Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients with Type 2 Diabetes
    Diabetes Care 1 Microvascular and Macrovascular Kamel Mohammedi,1 Mark Woodward,1,2,3 Yoichiro Hirakawa,1 Disease and Risk for Major Sophia Zoungas,1,4 Bryan Williams,5 Liu Lisheng,6 Anthony Rodgers,1 Peripheral Arterial Disease in Giuseppe Mancia,7 Bruce Neal,1 Stephen Harrap,8 Michel Marre,9,10,11 and Patients With Type 2 Diabetes John Chalmers,1 on behalf of the ADVANCE Collaborative Group DOI: 10.2337/dc16-0588 OBJECTIVE Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis in type 2 diabetes, but the relationship between other vascular diseases and PAD has been poorly investigated. We examined the impact of previous microvascular and 1The George Institute for Global Health, Univer- macrovascular disease on the risk of major PAD in patients with type 2 diabetes. sity of Sydney, Sydney, NSW, Australia 2The George Institute for Global Health, Univer- RESEARCH DESIGN AND METHODS sity of Oxford, Oxford, U.K. 3 We analyzed 10,624 patients with type 2 diabetes free from baseline major PAD in Department of Epidemiology, Johns Hopkins University, Baltimore, MD the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Con- 4Monash Centre for Health Research and Imple- trolled Evaluation (ADVANCE) clinical trial. The primary composite outcome was mentation, School of Public Health and Preven- major PAD defined as PAD-induced death, peripheral revascularization, lower- tive Medicine, Monash University, Clayton, PATHOPHYSIOLOGY/COMPLICATIONS limb amputation, or chronic ulceration. The secondary end points were the PAD Victoria, Australia 5Institute of Cardiovascular Sciences, University components considered separately. College London (UCL) and National Institute of Health Research UCL Hospitals Biomedical Re- RESULTS search Centre, London, U.K.
    [Show full text]
  • Microvascular and Macrovascular Disease and Risk for Major
    1796 Diabetes Care Volume 39, October 2016 Microvascular and Macrovascular Kamel Mohammedi,1 Mark Woodward,1,2,3 Yoichiro Hirakawa,1 Disease and Risk for Major Sophia Zoungas,1,4 Bryan Williams,5 Liu Lisheng,6 Anthony Rodgers,1 Peripheral Arterial Disease in Giuseppe Mancia,7 Bruce Neal,1 Stephen Harrap,8 Michel Marre,9,10,11 and Patients With Type 2 Diabetes John Chalmers,1 on behalf of the ADVANCE Collaborative Group Diabetes Care 2016;39:1796–1803 | DOI: 10.2337/dc16-0588 OBJECTIVE Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis in 1 type 2 diabetes, but the relationship between other vascular diseases and PAD has The George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia been poorly investigated. We examined the impact of previous microvascular and 2The George Institute for Global Health, Univer- macrovascular disease on the risk of major PAD in patients with type 2 diabetes. sity of Oxford, Oxford, U.K. 3Department of Epidemiology, Johns Hopkins RESEARCH DESIGN AND METHODS University, Baltimore, MD 4 We analyzed 10,624 patients with type 2 diabetes free from baseline major PAD in Monash Centre for Health Research and Imple- mentation, School of Public Health and Preven- the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Con- tive Medicine, Monash University, Clayton, trolled Evaluation (ADVANCE) clinical trial. The primary composite outcome was Victoria, Australia major PAD defined as PAD-induced death, peripheral revascularization, lower- 5Institute of Cardiovascular Sciences, University limb amputation, or chronic ulceration. The secondary end points were the PAD College London (UCL) and National Institute of Health Research UCL Hospitals Biomedical Re- components considered separately.
    [Show full text]
  • The Effectiveness of Disease and Case Management for People with Diabetes a Systematic Review Susan L
    The Effectiveness of Disease and Case Management for People with Diabetes A Systematic Review Susan L. Norris, MD, MPH, Phyllis J. Nichols, MPH, Carl J. Caspersen, PhD, MPH, Russell E. Glasgow, PhD, Michael M. Engelgau, MD, MSc, Leonard Jack Jr, PhD, MSc, George Isham, MD, Susan R. Snyder, PhD, Vilma G. Carande-Kulis, PhD, Sanford Garfield, PhD, Peter Briss, MD, David McCulloch, MD, and the Task Force on Community Preventive Services Overview: This report presents the results of a systematic review of the effectiveness and economic efficiency of disease management and case management for people with diabetes and forms the basis for recommendations by the Task Force on Community Preventive Services on the use of these two interventions. Evidence supports the effectiveness of disease management on glycemic control; on screening for diabetic retinopathy, foot lesions and peripheral neuropathy, and proteinuria; and on the monitoring of lipid concentrations. This evidence is applicable to adults with diabetes in managed care organizations and community clinics in the United States and Europe. Case management is effective in improving both glycemic control and provider monitoring of glycemic control. This evidence is applicable primarily in the U.S. managed care setting for adults with type 2 diabetes. Case management is effective both when delivered in conjunction with disease management and when delivered with one or more additional educational, reminder, or support interventions. Medical Subject Headings (MeSH): community health services, diabetes mellitus, evidence- based medicine, preventive health services, public health practice, review literature (Am J Prev Med 2002;22(4S):15–38) © 2002 American Journal of Preventive Medicine Introduction blindness in adults aged 20 to 74 years, and it is also the leading cause of end-stage renal disease, accounting for iabetes mellitus (diabetes) is a prevalent, costly about 40% of new cases.
    [Show full text]
  • Macrovascular Disease Due to Diabetes You Are at Greater Risk for Heart Attacks, Strokes and Poor Circulation to the Legs
    Diabetes Education – #25 Macrovascular Disease Due to Diabetes You are at greater risk for heart attacks, strokes and poor circulation to the legs. People with diabetes can have problems with their blood vessels. It is common for the arteries to get narrow. This can lead to disorders all through the body. The Metabolic Syndrome This is a group of problems: • too much belly fat • high blood pressure • high blood fats (“triglycerides”) • low HDL (“good”) cholesterol • high blood sugar People with the syndrome are at risk for heart problems early in life. And they are at risk for diabetes. Your body may not use insulin well. This may lead to cause the syndrome. The liver sends out too much sugar. The cells cannot take in the sugar for energy. The pancreas makes more insulin to make up for this. The result is more insulin in the blood. The body does not make enough insulin to keep up with insulin resistance. So, the blood sugar level may rise. The person may then go on to develop diabetes. Each of the problems listed above raises the risk of CHD (coronary heart disease). And they may play roles in strokes and PAD (peripheral artery disease). High insulin levels and a large waist boost the risk of death from CHD. You can help prevent CHD, strokes and PAD. You should watch your weight, blood pressure and cholesterol. Diabetes Education – #25 Coronary Heart Disease Some arteries carry blood to the heart. In CHD, these arteries get narrow. People who have diabetes are at risk for CHD.
    [Show full text]
  • Plasma Fatty Acids and the Risk of Vascular Disease and Mortality Outcomes in Individuals with Type 2 Diabetes: Results from the ADVANCE Study
    Diabetologia (2020) 63:1637–1647 https://doi.org/10.1007/s00125-020-05162-z ARTICLE Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study Katie Harris1 & Megumi Oshima1,2 & Naveed Sattar3 & Peter Würtz 4 & Min Jun1 & Paul Welsh3 & Pavel Hamet5 & Stephen Harrap6 & Neil Poulter7 & John Chalmers1 & Mark Woodward1,8,9 Received: 5 December 2019 /Accepted: 1 April 2020 / Published online: 8 May 2020 # The Author(s) 2020 Abstract Aims/hypothesis This biomarker study aimed to quantify the association of essential and other plasma fatty acid biomarkers with macrovascular disease, microvascular disease and death in individuals with type 2 diabetes. Methods A case-cohort study (N = 3576), including 654 macrovascular events, 341 microvascular events and 631 deaths during 5 years of (median) follow-up, was undertaken as a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) study (full details of the study design and primary endpoints of the ADVANCE trial and its case-cohort have been published previously). This current study considers new data: fatty acids measured from baseline plasma samples by proton NMR analysis. The fatty acids measured were n-3, docosahexaenoic acid (DHA), n-6, linoleic acid, and polyunsaturated, monounsaturated and saturated fatty acids. HRs were modelled per SD higher (percentage) fatty acid. C statistics and continuous net reclassification improvement were used to test the added value of fatty acids compared with traditional cardiovas- cular risk factors. Results After adjustment for traditional cardiovascular risk factors, an inverse association was observed for n-3 fatty acids and DHA with the risk of macrovascular events (HR [95% CI]: 0.87 [0.80, 0.95] and 0.88 [0.81, 0.96], respectively, per 1 SD higher percentage), and for n-3 fatty acids with the risk of death (HR 0.91 [95% CI 0.84, 0.99] per 1 SD higher percentage).
    [Show full text]
  • Glycemic Control and Macrovascular Disease in Types 1 and 2
    Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials Christoph Stettler, MD,a Sabin Allemann,a,b Peter Ju¨ni, MD,a,c Carole A. Cull, PhD,d Rury R. Holman, MD,d Matthias Egger, MD, MSc,a,c Stephan Kra¨henbu¨hl, MD,e and Peter Diem, MDb Bern, Switzerland; and Oxford, UK Background Uncertainty persists concerning the effect of improved long-term glycemic control on macrovascular disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any macrovascular event, cardiac events, stroke, and peripheral arterial disease, and the number needed to treat intensively during 10 years to prevent one macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events.
    [Show full text]
  • Presentations of Major Peripheral Arterial Disease and Risk of Major Outcomes in Patients with Type 2 Diabetes
    Mohammedi et al. Cardiovasc Diabetol (2016) 15:129 DOI 10.1186/s12933-016-0446-x Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‑ON study Kamel Mohammedi1*, Mark Woodward1,2,3, Yoichiro Hirakawa1, Sophia Zoungas1,4, Stephen Colagiuri5, Pavel Hamet6, Stephen Harrap7, Neil Poulter8, David R. Matthews9, Michel Marre10,11,12, John Chalmers1 and on behalf of the ADVANCE Collaborative Group Abstract Background: Peripheral arterial disease (PAD) is known to be associated with high cardiovascular risk, but the indi- vidual impact of PAD presentations on risk of macrovascular and microvascular events has not been reliably com- pared in patients with type 2 diabetes. We aimed to evaluate the impact of major PAD, and its different presentations, on the 10-year risk of death, major macrovascular events, and major clinical microvascular events in these patients. Methods: Participants in the action in diabetes and vascular disease: PreterAx and DiamicroN modified-release con- trolled evaluation (ADVANCE) trial and the ADVANCE-ON post-trial study were followed for a median of 5.0 (in-trial), 5.4 (post-trial), and 9.9 (overall) years. Major PAD at baseline was subdivided into lower-extremity chronic ulceration or amputation secondary to vascular disease and history of peripheral revascularization by angioplasty or surgery. Results: Among 11,140 participants, 516 (4.6 %) had major PAD at baseline: 300 (2.7 %) had lower-extremity ulcera- tion or amputation alone, 190 (1.7 %) had peripheral revascularization alone, and 26 (0.2 %) had both presentations.
    [Show full text]
  • Peripheral Artery Disease, Lower Limb Revascularization, and Amputation in Diabetes Patients with and Without Coronary Artery Di
    Cardiovascular and metabolic risk Open access Original research BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2020-001803 on 7 January 2021. Downloaded from Peripheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark Heart Registry Kevin Kris Warnakula Olesen ,1 Christine Gyldenkerne,1 Troels Thim,1 Reimar Wernich Thomsen,2 Michael Maeng1 To cite: Olesen KKW, ABSTRACT Gyldenkerne C, Thim T, et al. Introduction Patients with diabetes have increased Significance of this study Peripheral artery disease, risk of lower limb revascularization and amputation due lower limb revascularization, to higher risk of peripheral artery disease (PAD) and What is already known about this subject? and amputation in diabetes peripheral neuropathy. The additive effect of coronary ► Patients with diabetes have increased risk of low- patients with and without er limb amputation due to higher risk of peripheral coronary artery disease: a artery disease (CAD) is less clear. We examined the risk of PAD, lower limb revascularization, and amputation artery disease and peripheral neuropathy. The role cohort study from the Western of concomitant coronary artery disease (CAD) is Denmark Heart Registry. in diabetes and non- diabetes patients with and without unclear. BMJ Open Diab Res Care CAD in patients examined by coronary angiography 2021;9:e001803. doi:10.1136/ (CAG). What are the new findings? bmjdrc-2020-001803 Research design and methods We included all ► Patients with diabetes are at higher risk of lower patients undergoing CAG between 2003 and 2016 in limb amputation despite absence of CAD.
    [Show full text]
  • Chapter 19: Stroke and Diabetes
    CHAPTER 19 STROKE AND DIABETES Aleksandra Pikula, MD, Barbara V. Howard, PhD, and Sudha Seshadri, MD Dr. Aleksandra Pikula is Assistant Professor of Neurology, Department of Medicine, Division of Neurology, University of Toronto, Ontario, Canada. Dr. Barbara V. Howard is Professor of Medicine, Department of Medicine, Division of Endocrinology and Metabolism, Georgetown University Hospital, Washington, DC, and Senior Scientist, MedStar Health Research Institute, Hyattsville, MD. Dr. Sudha Seshadri is Professor of Neurology, Department of Neurology, Boston University, and Senior Investigator, Framingham Heart Study, Boston, MA. SUMMARY In the total population, stroke is the fifth most common cause of death and the leading neurological cause of long-term disability in the United States, accounting in 2011 for $34 billion in health care costs. With the advent of sensitive brain imaging techniques, it is common to observe magnetic resonance imaging evidence of subclinical vascular brain injury, such as covert brain infarcts (CBI) and white matter hyperintensities (WMH). In an unselected sample of persons age >65 years without a history of clinical events, 10%–15% had CBI and 95% had WMH. The subclinical findings do not cause abrupt clinical symptoms but are often associated with cognitive decline and with an increased risk of subsequent stroke. Therefore, the clinical and public health burden of cerebrovascular disease is far greater than that of overt clinical disease. This burden is higher in persons with diabetes. Diabetes, a risk equivalent for cardiovascular disease, has been recognized as one of the major risk factors for stroke and subclinical vascular brain injury, such as CBI, WMH, and vascular cognitive impairment.
    [Show full text]
  • Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease
    1 Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes Running title: Peripheral arterial disease in type 2 diabetes Kamel Mohammedi, MD, PHD1, Mark Woodward, PHD1,2,3, Yoichiro Hirakawa, MD, PHD1, Sophia Zoungas, MD, PHD1,4, more to be added …Michel Marre, MD, PHD5,6,7, John Chalmers, MD, PHD1; on behalf of the ADVANCE Collaborative Group 1The George Institute for Global Health, University of Sydney, Australia 2The George Institute for Global Health, University of Oxford, UK 3Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA 4Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia 5INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France 6Assistance Publique Hôpitaux de Paris, Bichat Hospital, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Paris, France 7Univ Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, Paris, France Bryan Williams affiliation – Institute of Cardiovascular Sciences University College London (UCL) and NIHR UCL Hospitals Biomedical Research Centre, London, UK. Author for correspondence: Professor John Chalmers The George Institute for Global Health, PO Box M201, Missenden Road, Camperdown, NSW 2050, Sydney, Australia Phone: +61 (0)2 9993 4587 Fax +61 (0)2 9993 4588 Email: [email protected] 2 Word count: abstract (250 words); main text (2633 words), 4 tables, 1 figure, online supplemental material (4 tables). 3 ABSTRACT OBJECTIVE: Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis in type 2 diabetes, but the relationship between vascular disease and PAD has been poorly investigated. We sought to examine the impact of previous microvascular and macrovascular disease on the risk of PAD in these patients.
    [Show full text]
  • Macrovascular Complications and Their Associated Risk Factors in Type 2 Diabetic Patients in Sana’A City, Yemen A
    املجلة الصحية لرشق املتوسط املجلد السادس عرش العدد الثامن Macrovascular complications and their associated risk factors in type 2 diabetic patients in Sana’a city, Yemen A. Al-Khawlani,1 Z.A. Atef 1 and A. Al-Ansi 1 املضاعفات يف اﻷوعية الكبرية وارتباطها بعوامل اﻻختطار لدى مرىض النمط الثاين من ّالسكري يف مدينة صنعاء، اليمن عبد الكريم حممد صالح اخلوﻻين، زايد أمحد عاطف، أمحد قاسم العنيس اخلﻻصـة: أجرى الباحثون ًمسحا ًعرضيا يف مدينة صنعاء، يف اليمن، يستهدف ُّالتعرف عىل معدل انتشار املضاعفات التي يمكن الوقاية منها يف اﻷوعية الكبرية، وارتباطها بضبط مستوى السكر وبغريها من عوامل اﻻختطار لدى مرىض النمط الثاين من ّالسكري. وﻻحظ الباحثون بعض مﻻمح أمراض اﻷوعية الكبرية لدى 79 ًمريضا )25.4%( من أصل 311 ًمريضا؛ فقد كان لدى 17.8% منهم مرض يف الرشايـني التاجية، ولدى %9.1 منهم ًمرضا باﻷوعية الطرفية، ولدى 5.8% منهم ًمرضا ًوعائيا ًدماغيا. كام وجد الباحثون ًترابطا ًإجيابيا يعتد به ً إحصائيابني مرض القلب التاجي وبني العمر، ومدة ّالسكري، وضغط الدم اﻻنقبايض، وضغط الدم اﻻنبساطي، واملعاجلة باﻷنسولني. كام ارتبط املرض الوعائي الطريف بالذكورة وبالعمر، وبمدة السكري، وبالتدخني احلايل للتبغ. أما املرض الوعائي الدماغي فقد ارتبط بضغط الدم اﻻنقبايض وضغط الدم اﻻنبساطي واملعاجلة باﻷنسولني. ABSTRACT A cross-sectional survey in Sana’a city, Yemen, aimed to determine the prevalence of preventable macrovascular complications and their association with glycaemic control and other risk factors in patients with type 2 diabetes mellitus (DM). Some features of macrovascular disease were found in 79 (25.4%) of the 311 patients: 17.8% had coronary heart disease, 9.1% had peripheral vascular disease and 5.8% had cerebrovascular disease.
    [Show full text]